Early Diagnosis of T1D Through An3body Screening
|
|
- Stella Cooper
- 5 years ago
- Views:
Transcription
1 Early Diagnosis of T1D Through An3body Screening Andrea Steck, M.D. Barbara Davis Center for Childhood Diabetes Keystone Conference July 15, 2017
2 Presenter Disclosure Andrea Steck Disclosed no conflict of interest
3 Outline Stages of type 1 diabetes Immunological markers and risk predic<on Metabolic markers and early diagnosis Studies offering screening and preven<on
4 Natural History of Type 1 Diabetes PUTATIVE ENVIRONMENTAL TRIGGER CELLULAR (T CELL) AUTOIMMUNITY HUMORAL AUTOANTIBODIES (IAA, GAD 65, IA- 2, ZnT8) BETA CELL MASS GENETIC PREDISPOSITION INSULITIS BETA CELL INJURY LOSS OF FIRST PHASE INSULIN RESPONSE (IVGTT) PRE - DIABETES GLUCOSE INTOLERANCE (OGTT) CLINICAL ONSET DIABETES TIME Eisenbarth, NEJM 1986
5 T1D Disease Progression Genetic Risk The Stages to Type 1 Diabetes Immune Activation Starting Point If you have a relative: 15x greater risk of developing T1D Immune Activation Beta cells are attacked Immune Response Immune Response Development of single autoantibody STAGE 1 STAGE 2 STAGE 3 STAGE 1 STAGE 2 STAGE 3 Normal Blood Sugar 2 autoantibodies START OF T1D Abnormal Blood Sugar 2 autoantibodies Clinical Diagnosis 2 autoantibodies STAGE 4 STAGE Longstanding T1D
6 ADA diagnos<c criteria
7 Tools for monitoring the natural history of prediabetes Markers of immune response to the beta- cell: Autoan<bodies Islet autoan<bodies: insulin, IA- 2, GAD65, ZnT8 T cell response Markers of metabolic changes: Oral glucose tolerance test HbA1c Con<nuous glucose monitoring
8 Progression to Diabetes in Children with Mul<ple Autoan<bodies Ziegler et al, DAISY, DIPP and BABYDIAB, JAMA 2013
9 HbA1c at onset is lower (7.2 vs. 10.9%) in DAISY compared to community children p< DAISY Community < >15 % HbA1c DAISY, Denver children 0-11 y old, Barker et al, Diabetes Care 2004
10 DKA and hospitaliza<on at T1D onset can be prevented by screening for islet autoan<bodies and educa<on! Hospitalization rate 100% 80% 60% DAISY children, age 0-11 years - FDR or pre-screened for HLA-DR,DQ at birth - followed for islet autoantibodies - diabetes education and monitoring - free glucometer, test strips 40% 20% 0% Denver community cases n=101 p < DAISY cases n=30 one 11-month old DAISY child was hospitalized Barker J, et al. DAISY. Diabetes
11 DKA at diagnosis: a growing problem in CO DKA present in 39% youth at T1D diagnosis Rewers A. et al. JAMA. 2015
12 Reduc<on of DKA at Onset Study Child < 2 years P value Child < 5 years P value TEDDY 6/40 (15%) 9/79 (11%) Sweden registry 51/129 (40%) /604 (17%) 0.45 SEARCH 29/58 (50%) < /275 (36%) < Finland registry 82/183 (45%) < /737 (19%) 0.11 German registry 235/435 (54%) < /1812 (32%) < Larsson et al, TEDDY Study, DC 2011
13 CGM as a marker of early glycemic changes in Ab+ subjects CGM variables: >140: % Time >140 mg/dl; >200: % Time >200 mg/dl OGTT values are baseline and 2- hr glucose values Dx: diagnosis of diabetes SD: standard devia<on Steck et al, Diabetes Care 2014
14 CGM measures in Ab+ vs Ab- subjects CGM Ab+ subjects (N=14) Ab- subjects (N=9) P value Mean glucose (mg/dl) Mean day* glucose (mg/dl) Max. day* sensor value (mg/dl) Max. night sensor value (mg/ dl) SD (mg/dl) CV (mg/dl) Range (mg/dl) % Time > 140 mg/dl % Time > 200 mg/dl AUC (mg/min/dl) AUC day* (mg/min/dl) AUC night (mg/min/dl) *Day: values between 6am and midnight AUC: area under the curve, calculated by the trapezoidal rule
15 CGM among Ab+ progressors vs. Ab+ non- progressors Variables Ab* positive progressors (N=5) Ab* positive nonprogressors (N=9) P value Mean glucose (mg/dl) Mean day glucose (mg/dl) Max. day SG value (mg/dl) SD (mg/dl) CV (mg/dl) Range (mg/dl) % Time > 140 mg/dl % Time > 200 mg/dl AUC (mg/min/dl) AUC day (mg/min/dl) AUC night (mg/min/dl) HbA1c, % (mean)
16 OGTT or random BG as markers for <me to T1D in children with mul<ple Ab (DIPP study) > 2 Abs IFG Median diabetes free survival <me indicated for each curve IGT BG 140 mg/dl OGTT group: 209/403 (52%) progressed to T1D Random BG group: 204/505 (40%) progressed to T1D (a) > 2 islet autoan<bodies (b) IFG in OGTT (solid line) or not (dashed line) (c) IGT in OGTT (solid line) or not (dashed line) (d) random BG 140 mg/dl (solid) or not (dashed) Helminen et al, Diabetologia 2015
17 DPTRS: Diabetes Preven<on Trial- Type 1 Risk Score DPTRS <6.5: low risk (<0.2) DPTRS >7.5: high risk (>0.5) The DPTRS includes the glucose sum of 30-, 60-, 90-, and 120- min values divided by 100, the C- pep<de sum of 30-, 60-, 90-, and 120- min values divided by 10, log fas<ng C- pep<de, log BMI, and age. Sosenko et al, Diabetes Care 2011
18 Residual beta- cell func<on in diabetes children followed prospec<vely TEDDY children iden<fied at birth with high- risk HLA and followed every 3 months un<l diabetes diagnosis were compared to age- matched children diagnosed with diabetes in the community HbA1c and MMTT were performed within 1 month of diabetes onset, then at 3, 6, and 12 months, and biannually thereaoer Steck AK et al, Pediatr Diabetes. 2017
19 TEDDY (N=43) Community (N=43) P-value Age at Dx, mean (years) 6.0 ± ± Gender Female, N (%) 20 (47) 27 (63) 0.21 BMI 16.0 ± ± Family history of diabetes, N (%) 9 (21) 2 (5) 0.04 Diabetes symptoms, N (%) 18 (42) 42 (98) <0.001 Diabetic ketoacidosis, N (%) 0 (0) 6 (14) 0.03 Hospitalization at diagnosis, N (%) 21 (49) 32 (74) 0.01 HLA-DR3/4,DQB1*0302,N (%) 24 (56) 4 (10) # of positive autoantibodies, N (%) 0 /1 / >2 1(4) / 5(19) / 21(78) 1(3) / 10(30) / 22(67) 0.58 Mean GADA level Mean IA-2A level Mean ZnT8A level HbA1c, % (mmol/mol) ( mmol/mol) ( mmol/mol) <0.001
20 C- pep<de AUC during MMTT in TEDDY cases and community controls during the first year aoer onset Box plots with minimum, first quartile, median, third quartile, and maximum values. The line in the box plots indicates the median value, while the mean is denoted by o for cases and + for controls. Outliers are marked as.
21 HbA1c in TEDDY cases and community controls during the first year follow- up aoer diagnosis of diabetes
22 Insulin dose in TEDDY cases and community controls during the first year follow- up aoer diagnosis of diabetes
23 IDAA1C in TEDDY cases and community controls during the first year follow- up aoer diagnosis of diabetes IDAA1C: Insulin-dose adjusted A1c: calculated as A1c (%) + [4 x insulin dose (units/kg/day)]
24 E<ology and Preven<on of T1D Find the cause of T1D General population cohort Sibling/offspring cohort Develop preven3on Public health screening Rela3ves and General Popula3on Colorado: 31,881 newborns screened 2,547 general popula3on and first- degree rela3ves followed Mul3na3onal: 424,000 newborns screened 8,677 high- risk children intensively followed omics studies Fr1da study 24
25 TrialNet Disease Preven<on Genetic Risk Immune Activation Immune Response Using knowledge gained through clinical research, TrialNet s mission is to prevent type 1 diabetes and stop disease progression by preserving insulin produc<on before and aoer diagnosis. STAGE 1 STAGE 2 STAGE 3 STAGE 4 25
26 TrialNet Pathway to Preven<on P2P Free screening for autoantibodies Anyone between age 1 and 45 with a FDR with T1D Anyone between age 1 and 20 with a 2nd degree rela<ve with T1D Those under 18 who do not have autoan<bodies can be retested yearly Based on results Look to enroll in clinical trial to preserve beta cell func<on Or monitor for disease progression Scott & Adam Pathway to Prevention Participants Keilyn Pathway to Prevention Participant Brooke, Emily & Ava Pathway to Prevention Participants
27 TrialNet Preven<on Studies Oral Insulin Study TrialNet Pathway to Prevention Study Abatacept Prevention Study Anti-CD3 Prevention Study
28 Capillary blood islet autoan<body screening The Fr1Da study in Germany is screening general popula<on children age 2 5 years for Ab The study uses capillary blood samples and a mul<plex ELISA assay for GAD, IA- 2, and IAA In the first 10 months, the study screened an average of 2,676 children per month General popula<on screening for Ab through collabora<on with primary care pediatricians is feasible Two pilot studies performed through TrialNet also showed the feasibility of Ab tes<ng by dried blood spots or capillary blood sampling Raab J & al, BMJ Open 2016 Liu Y & al, Diabet Med. 2017
29 ASK: Autoimmunity Screening for Kids Offer screening for pre- symptoma<c T1D and Celiac Disease Autoimmunity (CDA) to 55,000 Denver Metro Area children 2-17 years old Over a period of 3 years, with an<cipated 30% par<cipa<on rate, iden<fy: ~ 440 children with stage 1 or 2 T1D ~1100 children with confirmed celiac TGA 2
30 Specific Aims Enroll children with stage 1 or 2 T1D in intensive follow- up to prevent DKA and hospitaliza<on at onset of diabetes Enroll eligible children into preven<on trial to delay progression to diabetes Facilitate referral of children with celiac autoimmunity to pediatric GI services for treatment and follow- up Provide cost- effec<veness analyses of screening 3
31 Opportuni<es for Preven<on in ASK Par<cipants At diagnosis: 40% in DKA >80% hospitalized Insel R et al. Diabetes Care 2015
32 Take Away Messages Early diagnosis through prospec<ve studies is feasible (metabolic surveillance once mul<ple an<bodies are present) Subjects from prospec<ve studies have decreased rates of DKA and hospitaliza<ons Predic<on of risk is accurate Ongoing screening and preven<on trials for both rela<ves and general popula<on children
33 ADA Acknowledgments
Population Screening for T1D and Celiac Disease
Population Screening for T1D and Celiac Disease Marian Rewers, MD, PhD Barbara Davis Center for Diabetes I have no conflicts of interest to report Dysglycemia Opportunities for T1D Prevention Primary Secondary
More informationJDRF Research. Jessica Dunne, Ph.D. Director, Discovery Research
JDRF Research Jessica Dunne, Ph.D. Director, Discovery Research Saturday, March 11, 2017 Hello JESSICA DUNNE, PH.D. Joined JDRF in September 2008, Lead for Prevention program since its inception in July
More informationDysregulation of glucose metabolism in preclinical type 1 diabetes
Pediatric Diabetes 2016: 17(Suppl. 22): 25 30 doi: 10.1111/pedi.12392 All rights reserved Pediatric Diabetes Review Article Dysregulation of glucose metabolism in preclinical type 1 diabetes Veijola R,
More informationPrediction and Prevention of Type 1 Diabetes. How far to go?
Prediction and Prevention of Type 1 Diabetes. How far to go? Peter Colman Diabetes and Endocrinology Royal Melbourne Hospital Royal Melbourne Hospital Lancet, Saturday 30 th November 1974; p. 1279-1282
More informationT1D Clinical Research. Susanne Cabrera, MD Assistant Professor of Pediatrics Medical College of Wisconsin May 6, 2017
T1D Clinical Research Susanne Cabrera, MD Assistant Professor of Pediatrics Medical College of Wisconsin May 6, 2017 Why we need children and teens to participate in research Laboratory rats and mice are
More informationImmune Modulation of Type1 Diabetes
Immune Modulation of Type1 Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine Ideal Therapeutic
More informationChapter 11. Prediction of Type 1A Diabetes: The Natural History of the Prediabetic Period
Chapter 11 Prediction of Type 1A Diabetes: The Natural History of the Prediabetic Period Greenbaum et al Diabetes June 11, 212 Fall in C peptide During First 2 Years From Diagnosis: Evidence of at Least
More informationEarly Diagnosis and Intervention for Type 1 Diabetes (T1D) Progress from T1D TrialNet
Early Diagnosis and Intervention for Type 1 Diabetes (T1D) Progress from T1D TrialNet Wei Hao, M.D., Ph.D. Clinical Investigator Diabetes Clinical Research Program The TrialNet Clinical Network Hub & the
More informationPart XI Type 1 Diabetes
Part XI Type 1 Diabetes Introduction Åke Lernmark Epidemiology Type 1 diabetes is increasing worldwide and shows epidemic proportions in several countries or regions [1]. There is evidence to suggest that
More informationGAD65 Autoantibodies Detected by Electrochemiluminescence Assay Identify High Risk for Type 1 Diabetes
BRIEF REPORT GAD65 Autoantibodies Detected by Electrochemiluminescence Assay Identify High Risk for Type 1 Diabetes Dongmei Miao, K. Michelle Guyer, Fran Dong, Ling Jiang, Andrea K. Steck, Marian Rewers,
More informationWhat is New in Type 1 Diabetes? Prof. Åke Lernmark
What is New in Type 1 Diabetes? Lunds Universitet/CRC Skånes University Hospital SUS Malmö, Sweden 1 What s new in type 1 diabetes? Is the disease still increasing? What is the etiology? What is the pathogenesis?
More informationPrognostic Accuracy of Immunologic and Metabolic Markers for Type 1 Diabetes in a High-Risk Population
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Prognostic Accuracy of Immunologic and Metabolic Markers for Type 1 Diabetes in a High-Risk Population Receiver operating
More informationDistinguishing T1D vs. T2D in Childhood: a case report for discussion
Distinguishing T1D vs. T2D in Childhood: a case report for discussion Alba Morales, MD Associate Professor of Pediatrics Division of Pediatric Endocrinology and Diabetes Disclosure I have no financial
More informationPREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS)
PREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS) Pathways for Future Treatment and Management of Diabetes H. Peter Chase, MD Carousel of Hope Symposium Beverly Hilton, Beverly
More informationCeliac Disease: is it time for mass screening yet?
Celiac Disease: is it time for mass screening yet? Edwin Liu, MD Taplin Endowed Chair for Celiac Disease Director, Colorado Center for Celiac Disease Associate Professor of Pediatrics Digestive Health
More informationStaging of Type 1 Diabetes: Clinical Implications. April Deborah Hefty, MN, RN, CDE.
Staging of Type 1 Diabetes: TT Clinical Implications April 2016 Deborah Hefty, MN, RN, CDE dhefty@benaroyaresearch.org BRI s major contributions to type 1 diabetes research Identified type 1 diabetes susceptibility
More informationAltering The Course Of Type 1 Diabetes
Altering The Course Of Type 1 Diabetes JDRF TypeOneNation Summit 09.18.16 Stephen E. Gitelman, MD UCSF sgitelma@.ucsf.edu Today s Agenda My story The path to Type 1 Diabetes Prevention efforts New-onset
More informationWhat is a CGM? (Continuous Glucose Monitor) The Bionic Pancreas Is Coming
The Bionic Pancreas Is Coming Montana Diabetes Professional Conference October 23, 2014 H. Peter Chase, MD Professor of Pediatrics University of Colorado Barbara Davis Center Stanford: Bruce Buckingham,
More informationFlorida Network Symposium
Desmond Schatz MD University of Florida NE Florida Network Symposium In Conjunction with The 28th Annual Clinical Conference on Diabetes Increase Participation in Clinical Trials Accelerate the Path to
More informationType 2 Diabetes Mellitus in Adolescents PHIL ZEITLER MD, PHD SECTION OF ENDOCRINOLOGY DEPARTMENT OF PEDIATRICS UNIVERSITY OF COLORADO DENVER
Type 2 Diabetes Mellitus in Adolescents PHIL ZEITLER MD, PHD SECTION OF ENDOCRINOLOGY DEPARTMENT OF PEDIATRICS UNIVERSITY OF COLORADO DENVER Yes! Is Type 2 diabetes the same in kids as in adults? And No!
More informationReversion of b-cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study DOI: /dc
Diabetes Care 1 Reversion of b-cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study DOI: 10.2337/dc16-0181 Kendra Vehik, 1 Kristian F. Lynch, 1 Desmond A. Schatz, 2 Beena Akolkar, 3 William Hagopian,
More informationDesigning An)gen- specific Immunotherapy for Treatment of Type 1 Diabetes.
Designing An)gen- specific Immunotherapy for Treatment of Type 1 Diabetes. Kristin V. Tarbell Immune Tolerance Unit, Diabetes Endocrinology and Obesity Branch, NIDDK Outline Background on type 1 diabetes
More informationRay A. Kroc & Robert L. Kroc. BDC Lectureship 2014
Ray A. Kroc & Robert L. Kroc BDC Lectureship 2014 Ray Kroc (Big Mack) 1902-1984 Predominant establisher of the McDonald's Corporation (1961) Philanthropist: Research and treatment of alcoholism, diabetes,
More informationChapter 10. Humoral Autoimmunity 6/20/2012
Chapter 10 Humoral Autoimmunity 6/20/2012 DIPP Populations Study: Quartile Levels Insulin Autoantibodies (6 month post first IAA) and progression to Diabetes Parrika et al Diabetologia 2012 MSD ELECTROCHEMILUMINESCENT
More informationTargeting the Trimolecular Complex for Immune Intervention. Aaron Michels MD
Targeting the Trimolecular Complex for Immune Intervention Aaron Michels MD Disclosures Research Grant from Novartis. Research Grant from NovoNordisk. Take Home Points Type 1 diabetes is an immunologic
More informationKetoacidosis at diagnosis of type 1 diabetes: Effect of prospective studies with newborn genetic screening and follow up of risk children
Received: 30 January 2017 Revised: 5 April 2017 Accepted: 24 April 2017 DOI: 10.1111/pedi.12541 ORIGINAL ARTICLE Ketoacidosis at diagnosis of type 1 diabetes: Effect of prospective studies with newborn
More informationDiabetic Subjects Diagnosed Through the Diabetes Prevention Trial Type 1 (DPT-1) Are Often Asymptomatic With Normal A1C at Diabetes Onset
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Diabetic Subjects Diagnosed Through the Diabetes Prevention Trial Type 1 (DPT-1) Are Often Asymptomatic With Normal
More informationDiabetes Mellitus in the Pediatric Patient
Diabetes Mellitus in the Pediatric Patient William Bryant, M.D. Chief of Section Pediatric Endocrinology Children s Hospital at Scott & White Texas A&M University Temple, Texas Disclosures None Definitions
More informationAtypical and Ketosis Prone Diabetes. Ashok Balasubramanyam, MD Baylor College of Medicine Houston, Texas
Atypical and Ketosis Prone Diabetes Ashok Balasubramanyam, MD Baylor College of Medicine Houston, Texas Atypical Diabetes in the Spectrum Classified as T1D Classified as T2D Auto-immune T1D T2D A- - KPD
More informationBDC Keystone Genetics Type 1 Diabetes. Immunology of diabetes book with Teaching Slides
BDC Keystone Genetics Type 1 Diabetes www.barbaradaviscenter.org Immunology of diabetes book with Teaching Slides PRACTICAL Trailnet screens relatives and new onset patients for autoantibodies and HLA
More informationTreatment guideline for adult patients with type 1 diabetes?
Treatment guideline for adult patients with type 1 diabetes? Jae Hyeon Kim Division of Endocrinology and Metabolism, Samsung Medical Center, Sungkyunkwan University School of Medicine ICDM 2014 Treatment
More informationHbA 1c Predicts Time to Diagnosis of Type 1 Diabetes in Children at Risk
Diabetes Volume 64, May 2015 1719 Olli Helminen, 1 Susanna Aspholm, 2,3 Tytti Pokka, 1 Milla-Riikka Hautakangas, 1 Nora Haatanen, 1 Johanna Lempainen, 4,5 Jorma Ilonen, 4,6 Olli Simell, 5 Mikael Knip,
More informationIs It Time to Screen the General Population for Type 1 Diabetes?
Is It Time to Screen the General Population for Type 1 Diabetes? Kimber M Simmons, MD, MS 1 and Aaron W Michels, MD 2 1. Pediatric Endocrinology and Diabetes Fellow, Children s Hospital Colorado, Aurora,
More informationType 1 Diabetes in Children and Adolescents
Type 1 Diabetes in Children and Adolescents Joseph Wolfsdorf Division of Endocrinology Boston Children s Hospital Harvard Medical School joseph.wolfsdorf@childrens.harvard.edu I have no relevant financial
More informationType 2 Diabetes in Adolescents
Type 2 Diabetes in Adolescents Disclosures Paid consultant, Eli Lilly, Inc, Pediatric Type 2 Diabetes Clinical Trials Outline The burden of diabetes Treatment and Prevention Youth Diabetes Prevention Clinic
More informationDiabetes in Chronic Pancreatitis: When is it type 3c? Melena Bellin, MD Associate Professor, Pediatrics & Surgery Schulze Diabetes Institute
Diabetes in Chronic Pancreatitis: When is it type 3c? Melena Bellin, MD Associate Professor, Pediatrics & Surgery Schulze Diabetes Institute Disclosure Information Melena D. Bellin Disclosure of Relevant
More informationYes, We are Close to Preventing Diabetes!
Yes, We are Close to Preventing Diabetes! Peter A. Gottlieb, MD Barbara Davis Center University of Colorado Health Sciences Center Denver, CO Practical Ways to Achieve Targets in Diabetes Care, Keystone,
More informationCase- history. Lab results
Neda Rasouli, M.D. Associate Professor of Medicine Division of Endocrinology, UC Denver VA_ Eastern Colorado Health Care System Case- history 46 y/o AA male with BMI 37 presented in Oct 2001 with polyuria,
More informationIDDM1 and Multiple Family History of Type 1 Diabetes Combine to Identify Neonates at High Risk for Type 1 Diabetes
Metabolic Syndrome/Insulin Resistance Syndrome/Pre-Diabetes O R I G I N A L A R T I C L E IDDM1 and Multiple Family History of Type 1 Diabetes Combine to Identify Neonates at High Risk for Type 1 Diabetes
More informationT1D LANDSCAPE HLA INTERVENTION BIOMARKER SECONDARY PREVENTION BIG DATA GLOBAL RESEARCHERS VACCINE TIGEN-SPECIFIC TEDDY TRIAL NET RESEARCH TOOLS
ICROBIOME NOVEL DIAGNOSTICS OUTCOMES XSACKIE B VIRUSES COLLABORATIVE FUNDING ANDSCAPE EENING TOLERIZATION RIMARY PREVENTION PREVENTION LANDSCAPE A GUIDE FOR NAVIGATING EMERGING OPPORTUNITIES NOVEMBER 2014
More informationImmune therapy in type 1 diabetes mellitus.
Immune therapy in type 1 diabetes mellitus. Lernmark, Åke; Elding Larsson, Helena Published in: Nature Reviews Endocrinology DOI: 10.1038/nrendo.2012.237 2013 Link to publication Citation for published
More informationDelay of Type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial
Diabetologia (1998) 41: 536±541 Ó Springer-Verlag 1998 Delay of Type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial
More informationNew targets for prevention of type 1 diabetes George S. Eisenbarth Barbara Davis Center Unversity Colorado
New targets for prevention of type 1 diabetes George S. Eisenbarth Barbara Davis Center Unversity Colorado WEB BOOK: Immunology of Type 1 Diabetes HTTP://WWW.BARBARADAVISCENTER.ORG Board Member/Advisory
More informationJanice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND CLASSIFICATION OF DIABETES
Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND CLASSIFICATION OF DIABETES Objectives u At conclusion of the lecture the participant will be able to: 1. Differentiate between the classifications of diabetes
More informationS1-5 Tables (supplementary results) 3. S1-2 Figures (supplementary results).. 8. Details of the literature review... 10
Infant feeding and risk of type 1 diabetes in two large Scandinavian birth cohorts Authors: Nicolai A. Lund-Blix, Stine Dydensborg Sander, Ketil Størdal, Anne-Marie Nybo Andersen, Kjersti S. Rønningen,
More informationElimination of Dietary Gluten Does Not Reduce Titers of Type 1 Diabetes Associated Autoantibodies in High-Risk Subjects
Clinical Care/Education/Nutrition O R I G I N A L A R T I C L E Elimination of Dietary Gluten Does Not Reduce Titers of Type 1 Diabetes Associated Autoantibodies in High-Risk Subjects MICHAEL HUMMEL, MD
More informationIslet autoantibody phenotypes and incidence in children at increased risk for type 1 diabetes
Diabetologia (1) 8:317 33 DOI 1.17/s1-1-367-y ARTICLE Islet autoantibody phenotypes and incidence in children at increased risk for type 1 diabetes Eleni Z. Giannopoulou 1 & Christiane Winkler 1, & Ruth
More informationGestational Diabetes: Long Term Metabolic Consequences. Outline 5/27/2014
Gestational Diabetes: Long Term Metabolic Consequences Gladys (Sandy) Ramos, MD Associate Clinical Professor Maternal Fetal Medicine Outline Population rates of obesity and T2DM Obesity and metabolic syndrome
More informationA Study on the Presence of Islets Cell Autoantibodies in Non- Insulin Requiring Young Diabetic Patients
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 14, Issue 12 Ver. VI (Dec. 2015), PP 119-123 www.iosrjournals.org A Study on the Presence of Islets Cell
More informationWhen Will CGM Replace SMBG? Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida
When Will CGM Replace SMBG? Roy W. Beck, MD, PhD JAEB Center for Health Research Tampa, Florida Financial Disclosures Dr. Beck does not have any personal conflicts of interest His employer, the JAEB Center
More informationType 1 diabetes (T1D) is often first recognized
PERSPECTIVES IN DIABETES The Metabolic Progression to Type 1 Diabetes as Indicated by Serial Oral Glucose Tolerance Testing in the Diabetes Prevention Trial Type 1 Jay M. Sosenko, 1 Jay S. Skyler, 1 Kevan
More informationPOSITION STATEMENT. May Early diagnosis of children with Type 1 diabetes. Key points
POSITION STATEMENT Title Date Early diagnosis of children with Type 1 diabetes May 2015 Key points Early diagnosis of Type 1 diabetes is essential to allow treatment to start as soon as possible. The classic
More informationDiabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE
Diabetes: Definition Pathophysiology Treatment Goals By Scott Magee, MD, FACE Disclosures No disclosures to report Definition of Diabetes Mellitus Diabetes Mellitus comprises a group of disorders characterized
More informationType 1 Diabetes and the Environment: a Focus on Dietary Factors
Type 1 Diabetes and the Environment: a Focus on Dietary Factors CHE Partnership Call November 12, 2014 Jill M. Norris, MPH, PhD Professor and Chair Department of Epidemiology Colorado School of Public
More informationGeorge Ford MD MS Assistant Professor Pediatric Endocrinology ETSU and Niswonger Children s Hospital
George Ford MD MS Assistant Professor Pediatric Endocrinology ETSU and Niswonger Children s Hospital Disclosure Statement of Financial Interest I, George Ford MD MS, DO NOT have a financial interest/arrangement
More informationResidual C-peptide in type 1 diabetes: what do we really know?
Pediatric Diabetes 2014: 15: 84 90 doi: 10.1111/pedi.12135 All rights reserved 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. Pediatric Diabetes Review Article Residual C-peptide in type
More informationIslet autoimmunity leading to type 1 diabetes develops
CLINICAL RESEARCH ARTICLE Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in Type 1 Diabetes Relatives Emanuele Bosi, 1 David C. Boulware, 2 Dorothy J. Becker, 3 Jane
More informationBaseline heterogeneity in glucose metabolism marks the risk for type 1 diabetes and complicates secondary prevention.
Baseline heterogeneity in glucose metabolism marks the risk for type 1 diabetes and complicates secondary prevention. Elding Larsson, Helena; Larsson, Christer; Lernmark, Åke Published in: Acta Diabetologica
More informationThe In-Clinic Close Loop Experience in the US
The In-Clinic Close Loop Experience in the US Keystone Symposium, Practical Ways to Achieve Targets in Diabetes Care July 14, 2012 Francine Ratner Kaufman, MD Chief Medical Officer, VP Global Medical,
More informationVariation in Glucose and A1c Measurement: Which Diabetes Test is Best?
Variation in Glucose and A1c Measurement: Which Diabetes Test is Best? Martha E Lyon, PhD, DABCC, FAACC Division of Clinical Biochemistry Department of Pathology & Laboratory Medicine Saskatchewan Health
More informationINCIDENCE OF CHILDHOOD TYPE 1 DIABETES IN 14 EUROPEAN COUNTRIES INCLUDING ALL NORDIC COUNTRIES
INCIDENCE OF CHILDHOOD TYPE 1 DIABETES IN 14 EUROPEAN COUNTRIES 1989-1998 INCLUDING ALL NORDIC COUNTRIES FINLAND Sardinia SWEDEN NORWAY UK DENMARK ICELAND Estonia France Greece Italy Lithuania Latvia Romania
More informationIPS Modern management of childhood diabetes mellitus
Modern management of childhood diabetes mellitus Professor Philippe LYSY, MD PhD Pediatric endocrinology and diabetology Institut de Recherche Expérimentale et Clinique Université Catholique de Louvain
More informationCase 2: A 42 year-old male with a new diagnosis of diabetes mellitus. History - 1
Case 2: A 42 year-old male with a new diagnosis of diabetes mellitus Bruce Knutsen, MD Michael Slag, MD Lisa Thomas, RN, CDE Essentia Health Diabetes and Endocrinology Conference October 14, 2011 History
More informationBenaroya Research Institute. Update on Type 1 Diabetes Trials. to Save Beta Cells. Carla Greenbaum MD. Seattle, WA
Benaroya Research Institute Update on Type 1 Diabetes Trials Carla Greenbaum MD Seattle, WA to Save Beta Cells 1552 BC earliest written record of DM 1 st Breakthrough in understanding: 1889 The problem
More informationC Peptide and Type 1 Diabetes: Concise Review of Fundamental Concepts
C Peptide and Type 1 Diabetes: Concise Review of Fundamental Concepts Authors: Radhika R Narla, MD 1,2 Jerry P Palmer 1,2 Affiliations 1 Division of Metabolism, Endocrinology and Nutrition, Department
More informationLessons From The Type 1 Diabetes Exchange
Lessons From The Type 1 Diabetes Exchange Andrew Ahmann, MD Harold Schnitzer Diabetes Health Center at OHSU Presenter Disclosure Information In compliance with the accrediting board policies, the American
More informationUpdate on Continuous Glucose Monitoring (CGM) Technology in Diabetes. Elena Toschi, MD November 12, 2016
Update on Continuous Glucose Monitoring (CGM) Technology in Diabetes Elena Toschi, MD November 12, 2016 Presenter Disclosure Information Elena Toschi, MD No financial disclosure Objectives: Use of CGM
More informationDiabetes Management: Current High Tech Innovations
Diabetes Management: Current High Tech Innovations How Far We ve Come in the Last 40 Years William V. Tamborlane, MD Department of Pediatrics Yale School of Medicine Disclosures I am a consultant for:
More informationComprehensive Screening Detects Undiagnosed Autoimmunity In Adult-onset Type 2 Diabetes
Comprehensive Screening Detects Undiagnosed Autoimmunity In Adult-onset Type 2 Diabetes SRINIVASA R. NAGALLA, MD, PATURI V. RAO, MD, CARYN K. SNYDER, MPH, JERRY P. PALMER, MD, CHARLES T. ROBERTS, PhD DiabetOmics,
More informationCare for Children with Diabetes: Evaluation, Management, and Future Directions
Care for Children with Diabetes: Evaluation, Management, and Future Directions Ayer s Children s Medical Center 2016 General Pediatric Conference September 17, 2016 William E. Russell, MD Jennifer Kelley,
More informationClinical and Laboratory Characteristics of Childhood Diabetes Mellitus: A Single-Center Study from 2000 to 2013
Original Article www.cmj.ac.kr Clinical and Laboratory Characteristics of Childhood Diabetes Mellitus: A Single-Center Study from 2000 to 2013 Tae Hyun Park 1, Min Sun Kim 1,2, * and Dae-Yeol Lee 1,2 1
More informationMetabolomics and systems biology approaches to study health and disease. Matej Oreši
Metabolomics and systems biology approaches to study health and disease Matej Oreši 14.12.2011 1/19/2012 2 Biomarker concept in domain of human health [Wikipedia definition] A substance used as an indicator
More informationLONG-TERM INVESTIGATIVE FOLLOW-UP IN TRIALNET (LIFT) (Protocol TN-16)
TrialNet Protocol TN16 LIFT Protocol Version: 2.0 12FEB2015 LONG-TERM INVESTIGATIVE FOLLOW-UP IN TRIALNET (LIFT) (Protocol TN-16) Version: 2.0 12FEB2015 Sponsored by the National Institute of Diabetes
More informationTrialNet NATURAL HISTORY STUDY OF THE DEVELOPMENT OF TYPE 1 DIABETES: A PATHWAY TO PREVENTION
TrialNet NATURAL HISTORY STUDY OF THE DEVELOPMENT OF TYPE 1 DIABETES: A PATHWAY TO PREVENTION TYPE 1 DIABETES TRIALNET Researchers in this study are part of a larger group called Type 1 Diabetes TrialNet.
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Baidal DA, Ricordi C, Berman DM, et al. Bioengineering of an
More informationAnti-islet autoantibodies in Japanese type 1 diabetes
15 th Korea Japan Symposium on Diabetes Anti-islet autoantibodies in Japanese type 1 diabetes Eiji Kawasaki, Katsumi Eguchi Nagasaki University Hospital, Nagasaki, Japan November 20 21, 21 2009 Cheju Islend
More informationEvgenija Homšak,M.Ph., M.Sc., EuSpLM. Department for laboratory diagnostics University Clinical Centre Maribor Slovenia
Evgenija Homšak,M.Ph., M.Sc., EuSpLM. Department for laboratory diagnostics University Clinical Centre Maribor Slovenia 14th EFLM Continuing Postgraduate Course in Clinical Chemistry and Laboratory Medicine
More informationUpdate on Type 1 Diabetes Trials to Save Beta Cells
Benaroya Research Institute Carla Greenbaum MD Seattle, WA Update on Type 1 Diabetes Trials to Save Beta Cells 1552 BC earliest written record of DM 1 st Breakthrough in understanding: 1889 The problem
More informationPATHOPHYSIOLOGY Diabetes Volume 65, July Diabetes 2016;65: DOI: /db
1988 Diabetes Volume 65, July 2016 Helena Elding Larsson, 1 Kendra Vehik, 2 Michael J. Haller, 3 Xiang Liu, 2 Beena Akolkar, 4 William Hagopian, 5 Jeffrey Krischer, 2 Åke Lernmark, 1 Jin-Xiong She, 6 Olli
More informationClinical practice guidelines in management of type 1 diabetic patients
2016 International Conference on Diabetes and Metabolism October 13 ~ 15, 2016, Grand Hilton Seoul Hotel, Korea S2 Behavioral medicine/education : Current management of type 1 diabetes in real clinical
More informationType 1 Diabetes-Pathophysiology, Diagnosis, and Long-Term Complications. Alejandro J de la Torre Pediatric Endocrinology 10/17/2014
Type 1 Diabetes-Pathophysiology, Diagnosis, and Long-Term Complications Alejandro J de la Torre Pediatric Endocrinology 10/17/2014 Objectives Understand the pathophysiology of Type 1 diabetes. Be familiar
More informationCeliac Disease. Marian Rewers, MD, PhD. Professor & Clinical Director Barbara Davis Center for Diabetes University of Colorado School of Medicine
Celiac Disease Marian Rewers, MD, PhD Professor & Clinical Director Barbara Davis Center for Diabetes University of Colorado School of Medicine No relevant financial relationships with any commercial interests
More informationType 1 and Type 2 Diabetes among Youths in Jordan: Incidence and Trends for the period ( ) Abstract Acknowledgement 1.
Type 1 and Type 2 Diabetes among Youths in Jordan: Incidence and Trends for the period (2011-2016) Dr. Alghtani Fehaid Mohammed N Dr. Alanazi Saqqar Abdulelah S Dr. Alshahrani Adel Mohammed S Dr. Alhejaili
More informationMore Than 1 Year of Hybrid Closed Loop in Pediatrics. Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center
More Than 1 Year of Hybrid Closed Loop in Pediatrics Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center Disclosure Dr. Forlenza has served as a consultant for Abbott Diabetes Care and conducts
More informationAdvances in Managing Diabetes in Youth. March 1, 2012
Advances in Managing Diabetes in Youth March 1, 2012 Diabetes in Youth: An Update The Problem Increasing Incidence of Type 1 Diabetes The Cause New Information on an Enterovirus connection New Therapy
More informationDepleting T cells in newly diagnosed autoimmune (type 1) diabetes--are we getting anywhere?
Depleting T cells in newly diagnosed autoimmune (type 1) diabetes--are we getting anywhere? Lernmark, Åke Published in: Diabetes DOI: 10.2337/db13-1207 Published: 2013-01-01 Link to publication Citation
More information39 year old F with sickle cell anemia presenting with pain crisis. Jess Hwang 11/8/12
39 year old F with sickle cell anemia presenting with pain crisis Jess Hwang 11/8/12 HPI Knee and back pain typical of usual crises Nausea and vomiting 2 days prior to admission Had previously been on
More informationPreventing the Predictable. Type 1 diabetes in children: Risk factors and impact of participation in prospective follow-up
Preventing the Predictable. Type 1 diabetes in children: Risk factors and impact of participation in prospective follow-up Lundgren, Markus 2017 Document Version: Förlagets slutgiltiga version Link to
More informationHOW CAN WE PREVENT RECURRENT-DKA?
pinterest HOW CAN WE PREVENT RECURRENT-DKA? Birgit Rami-Merhar DKA is not only a problem at the onset of T1D T1D-children at risk for recurrent DKA: 1-10%/patient/year (ISPAD 2014) mortality rate from
More informationVishwanath Pattan Endocrinology Wyoming Medical Center
Vishwanath Pattan Endocrinology Wyoming Medical Center Disclosure Holdings in Tandem Non for this Training Introduction In the United States, 5 to 6 percent of pregnancies almost 250,000 women are affected
More informationThe Changing Face of Diabetes in Youth: Lessons Learned from Studies of Type 2
Page of Annals of the New York Academy of Sciences 0 0 0 0 0 The Changing Face of Diabetes in Youth: Lessons Learned from Studies of Type Diabetes Tamara S. Hannon and Silva A. Arslanian Indiana University
More informationDiabetes mellitus is a complex of syndromes characterized metabolically by hyperglycemia and altered glucose metabolism, and associated
Diabetes mellitus is a complex of syndromes characterized metabolically by hyperglycemia and altered glucose metabolism, and associated pathologically with specific microvascular and macrovascular complications.
More informationJDRF RESEARCH UPDATE. Daniel Finan, Ph.D. Research Director
JDRF RESEARCH UPDATE Daniel Finan, Ph.D. Research Director March 10, 2018 PRESENTER Daniel Finan Biomedical engineer B.S. Chemical Engineering University of Colorado, 2003 Ph.D. Chemical Engineering UC
More informationReduction in Hypoglycemia and No Increase in A1C with Threshold-Based Sensor-Augmented Pump (SAP) Insulin Suspension: ASPIRE In-Home
Reduction in Hypoglycemia and No Increase in A1C with Threshold-Based Sensor-Augmented Pump (SAP) Insulin Suspension: ASPIRE In-Home Richard M. Bergenstal 1, David C. Klonoff 2, Bruce W. Bode 3, Satish
More informationRELATIONSHIP OF CLINICAL FACTORS WITH ADIPONECTIN AND LEPTIN IN CHILDREN WITH NEWLY DIAGNOSED TYPE 1 DIABETES. Yuan Gu
RELATIONSHIP OF CLINICAL FACTORS WITH ADIPONECTIN AND LEPTIN IN CHILDREN WITH NEWLY DIAGNOSED TYPE 1 DIABETES by Yuan Gu BE, Nanjing Institute of Technology, China, 2006 ME, University of Shanghai for
More informationDiabetes Management in Toddlers/Preschoolers (<6 yo)
Diabetes Management in Toddlers/Preschoolers (
More informationPrevalence of Type 1 Diabetes auto-antibodies (GADA, IA2, IAA) in overweight and obese children
Diabetes Care Publish Ahead of Print, published online December 29, 2009 Type 1 Diabetes auto-antibodies in obese children Prevalence of Type 1 Diabetes auto-antibodies (GADA, IA2, IAA) in overweight and
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationT1D Exchange Clinic Registry: 25,000 strong! What is it and what have we learned to date? Georgeanna J Klingensmith, MD Barbara Davis Center
T1D Exchange Clinic Registry: 25,000 strong! What is it and what have we learned to date? Georgeanna J Klingensmith, MD Barbara Davis Center T1D Exchange Mission and Goals Improve outcomes of people touched
More informationJEFFREY P. KRISCHER, PHD 1 JAY M. SOSENKO, MD 4 JAY S. SKYLER, MD 4 ON BEHALF OF THE DIABETES PREVENTION TRIAL TYPE 1 (DPT-1) STUDY GROUP
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Prognostic Performance of Metabolic Indexes in Predicting Onset of Type 1 Diabetes PING XU, MPH 1 YOUGUI WU, PHD 2
More information